respiratori
infect
main
caus
hospit
children
common
reason
antibiot
treatment
rapid
antigen
detect
test
radt
pointofcar
poc
multiplex
polymeras
chain
reaction
mpcr
base
assay
provid
fast
case
latter
reliabl
detect
viral
pathogen
poc
diagnost
tool
report
reduc
prescript
antibiot
drug
nonetheless
prescript
rate
antibiot
respiratori
infect
germani
still
higher
recommend
european
surveil
antimicrobi
consumpt
project
esac
human
metapneumoviru
first
describ
belong
famili
paramyxovirida
subfamili
pneumovirina
genu
metapneumoviru
close
relat
respiratori
syncyti
viru
rsv
member
subfamili
differ
genu
pneumoviru
patient
suffer
hmpv
infect
first
time
show
symptom
resembl
rsv
ill
age
year
nearli
test
children
show
posit
serolog
hmpv
howev
reinfect
report
besid
close
phylogenet
relationship
hmpv
rsv
clinic
symptom
similar
rate
indistinguish
like
rsv
hmpv
caus
uncompl
infect
upper
airway
sever
bronchiol
communityacquir
viral
pneumonia
accord
preexist
studi
hmpv
detect
pathogen
pediatr
patient
symptom
acut
respiratori
infect
singlecent
studi
analyz
data
children
found
hmpv
trigger
frequent
antibiot
treatment
compar
viral
pathogen
aim
studi
identifi
characterist
featur
hmpv
infect
provid
rational
reduc
prescript
antibiot
drug
children
admit
center
pediatr
adolesc
medicin
mainz
univers
medic
center
acut
respiratori
infect
januari
januari
includ
present
studi
data
children
retrospect
analyz
clinic
find
laboratori
paramet
antibiot
therapi
inhal
treatment
admitt
inpati
treatment
consent
given
anonym
scientif
analysi
data
acquir
diagnost
treatment
materi
diagnost
obtain
everi
patient
emerg
depart
admiss
inpati
treatment
collect
nasopharyng
swap
commerci
provid
suction
system
recent
describ
inhous
develop
multiplex
revers
transcriptas
polymeras
chain
reaction
combin
microwel
hybrid
assay
mrtpcrelisa
perform
pathogen
detect
follow
virus
bacteri
pathogen
could
detect
singl
sampl
enteroviru
influenza
viru
type
type
b
respiratori
syncyti
viru
rsv
parainfluenza
viru
type
type
type
type
adenoviru
rhinoviru
human
metapneumoviru
hmpv
coronaviru
reoviru
mycoplasma
pneumonia
chlamydophila
pneumonia
bordetella
pertussi
bordetella
parapertussi
legionella
pneumophila
mrtpcrelisa
perform
weekday
certain
number
sampl
accumul
could
process
one
run
sampl
collect
final
result
mrtpcrelisa
took
averag
work
day
rsv
influenza
radt
certest
biotec
sl
perform
poc
diagnost
everi
patient
admiss
sensit
rsv
specif
data
provid
manufactur
reflect
result
comparison
certest
radt
anoth
radt
evalu
pcr
provid
refer
radt
pool
sensit
pool
specif
evalu
pcr
cultur
data
obtain
clinic
inform
system
data
analyz
graphpad
prism
version
graphpad
softwar
inc
statist
signific
evalu
fisher
exact
test
confid
interv
respect
method
alpha
multipl
test
period
januari
januari
total
sampl
analyz
mrtpcrelisa
nasal
secret
deriv
children
sign
lower
respiratori
tract
lrt
infect
posit
mrtpcrelisa
result
subsequ
analysi
present
result
patient
least
one
identifi
pathogen
n
median
age
month
iqr
month
total
male
rhinoviru
detect
frequent
total
patient
patient
hmpv
rsv
detect
hmpv
rsv
display
similar
distinct
season
pattern
increas
incid
novemb
april
hmpv
show
higher
incid
year
follow
lower
incid
next
year
fig
accord
publish
data
author
found
highest
incid
februari
march
found
peak
parallel
rsv
season
complet
shown
hmpv
occur
rsv
season
hmpv
infect
detect
march
may
rsvinfect
children
significantli
younger
children
hmpv
infect
rsv
median
age
vs
month
hmpv
infect
fig
tabl
differ
length
hospit
stay
day
rsv
vs
day
hmpv
mention
symptom
hmpv
infect
easili
discrimin
rsv
infect
even
describ
undistinguish
valid
clinic
symptom
compar
frequenc
inhal
therapi
applic
system
steroid
surrog
pulmonari
obstruct
fig
tabl
prescript
inhal
salbutamol
combin
salbutamol
ipratropium
bromid
epinephrin
inhal
summar
follow
section
inhal
therapi
patient
posit
test
hmpv
receiv
inhal
therapi
contrast
patient
posit
rsv
compar
patient
respiratori
infect
hmpv
rsv
receiv
inhal
therapi
odd
ratio
receiv
treatment
significantli
higher
hmpv
rsv
infect
respect
compar
hmpv
rsv
directli
slightli
higher
chanc
treat
inhal
therapi
patient
posit
test
rsv
mrtpcrelisa
laboratori
paramet
includ
white
blood
cell
count
wbc
creactiv
protein
crp
differ
hmpv
rsv
median
respiratori
virus
test
tabl
patient
includ
studi
receiv
radt
rsv
rsvposit
children
mrtpcrelisa
posit
rsvradt
patient
hmpv
mrtpcrelisa
show
posit
rsvradt
take
mrtpcrelisa
test
account
patient
posit
rsvradt
receiv
antibiot
contrast
antibiot
treatment
neg
rsvradt
result
signific
reduct
antibiot
therapi
associ
posit
rsvradt
result
see
tabl
outlin
result
mrtpcrelisa
avail
averag
day
nasal
specimen
obtain
thu
mrtpcrelisa
result
influenc
initi
treatment
regimen
patient
notabl
antibiot
treatment
differ
significantli
group
evalu
pathogen
patient
posit
hmpv
mrtpcrelisa
treat
antibiot
patient
rsv
infect
detect
mrtpcrelisa
receiv
antibiot
treatment
other
compar
latter
patient
posit
hmpv
result
two
time
like
receiv
antibiot
therapi
signific
differ
rsv
remain
pathogen
tabl
fig
januari
januari
nasal
secret
hospit
children
acut
lrt
infect
investig
mrtpcrelisa
radt
clinic
laboratori
data
patient
posit
mrtpcrelisa
result
collect
addit
knowledg
one
largest
evalu
cohort
hospit
children
acut
respiratori
tract
infect
materi
collect
done
per
nasal
swab
nasopharyng
aspir
npa
npa
highest
yield
detect
respiratori
virus
even
higher
bronchoalveolar
lavag
nasal
swab
moder
decreas
sensit
viru
detect
npa
gener
detect
rate
differ
respiratori
viru
especi
high
rsvinfect
patient
detect
rate
common
streptococcu
pneumonia
haemophilu
influenza
atyp
bacteri
pathogen
pneumonia
c
pneumonia
compar
npa
nasal
swab
overal
children
treat
antibiot
children
viral
infect
receiv
antibiot
treatment
bacteri
pathogen
could
detect
mrtpcrelisa
howev
typic
bacteri
pathogen
lrt
infect
pneumonia
h
influenza
moraxella
catarrhali
detect
appli
pcr
panel
result
mrtpcrelisa
avail
decis
antibiot
therapi
made
accord
recent
report
studi
popul
found
posit
hmpv
hmpv
infect
hold
two
time
higher
probabl
antibiot
treatment
compar
viral
infect
rsv
infect
significantli
less
frequent
treat
antibiot
cohort
hmpv
often
compar
rsv
due
close
phylogenet
relat
similar
symptom
airway
obstruct
bronchiol
hospit
rsvinfect
children
tend
younger
hmpv
infect
commonli
observ
age
pattern
saw
nearli
parallel
occurr
concern
season
distribut
describ
precis
hmpv
occur
shortli
parallel
shortli
rsv
season
novemb
april
studi
observ
hmpv
occur
mainli
rsv
infect
season
present
studi
differ
could
observ
inflamm
paramet
eg
crp
wbc
bodi
temperatur
hmpv
rsv
median
pathogen
airway
obstruct
caus
rsv
hmpv
pronounc
compar
investig
pathogen
interestingli
rsv
frequent
treat
inhal
system
steroid
hmpv
might
confound
inhous
standard
protocol
requir
inhal
epinephrin
hyperton
salin
children
posit
rsvradt
may
reflect
clinic
appear
patient
epinehphrin
inhal
shown
reduc
symptom
bronchiol
especi
first
h
influenc
length
hospit
stay
contrast
recommend
concern
antibiot
therapi
rsv
infect
inhous
protocol
mention
symptom
hmpv
rsv
infect
describ
undistinguish
wherea
studi
see
bronchiol
children
rsv
infect
pneumonia
hmpvposit
children
moe
et
al
adjust
clinic
laboratori
radiograph
find
age
patient
led
disappear
detect
differ
sinc
children
rsv
infect
significantli
younger
hmpv
infect
diagnosi
bronchiol
seem
common
wherea
elev
crp
valu
wheez
radiolog
sign
pneumonia
frequent
patient
hmpv
infect
regard
discuss
studi
differ
sever
diseas
hmpv
rsv
determin
oxygen
therapi
length
hospit
stay
admiss
intens
care
unit
take
account
highli
interest
children
present
compar
symptom
treat
differ
keep
mind
posit
rsvradt
led
increas
prescript
inhal
therapi
assum
might
also
relat
reduc
rate
antibiot
treatment
posit
result
rsvradt
associ
significantli
reduc
prescript
antibiot
clear
reduct
antibiot
prescript
rate
posit
rsvradt
practition
seem
inclin
start
symptomat
therapi
inhal
refrain
antibiot
treatment
clinic
present
patient
radt
indic
rsv
infect
antibiot
therapi
radt
neg
patient
might
trigger
uncertainti
etiolog
infect
sever
symptom
laboratori
find
cours
antibiot
therapi
might
also
trigger
assum
bacteri
coinfect
well
describ
rsv
infect
hmpv
one
studi
indic
superinfect
pneumonia
occur
sinc
pneumococc
vaccin
reduc
hospit
children
hmpvassoci
pneumonia
bacteri
coinfect
even
children
present
wheez
estim
rang
howev
possibl
draw
clear
distinct
bacteri
infect
colon
neither
detect
bacteri
pathogen
clinic
radiolog
sign
pneumonia
decis
antibiot
treatment
posit
bacteri
cultur
could
correl
posit
studi
high
serum
level
crp
exceed
mgl
might
indic
bacteri
infect
rsv
infect
also
lower
concentr
crp
hint
bacteri
coinfect
sinc
rsv
known
suppress
product
proinflammatori
protein
high
viral
load
rsv
associ
decreas
crp
serum
concentr
hmpv
lack
gene
code
protein
allow
rsv
reduc
host
immun
respons
contrast
lower
concentr
interleukin
found
children
infect
hmpv
children
suffer
rsv
infect
underlin
challeng
decisionmak
concern
antibiot
treatment
children
respiratori
tract
infect
studi
antibiot
treatment
like
trigger
elev
laboratori
valu
indic
inflamm
eg
particularli
pronounc
children
adenoviru
infect
andor
clinic
symptom
often
associ
bacteri
infect
like
crackl
auscult
crackl
regard
hallmark
pneumonia
found
hmpv
rsv
infect
result
mention
might
confound
asymptomat
carrier
viral
pathogen
children
persist
detect
nucleic
acid
viral
infect
week
even
month
ago
well
describ
adenovirus
rhinovirus
coronavirus
wherea
hmpv
rsv
parainfluenza
virus
posit
result
pcrdiagnost
strongli
indic
detect
pathogen
caus
acut
infect
certain
limit
studi
fact
bacteri
superinfect
could
complet
rule
limit
includ
lack
detail
preexist
ill
radiograph
find
need
oxygen
particular
valu
present
studi
high
number
includ
patient
mrtpcrelisa
pathogen
detect
everi
patient
long
observ
period
year
clinic
applic
anoth
multiplex
pcrbase
pointofcar
test
detect
viral
bacteri
pathogen
within
h
increasingli
use
inpati
treatment
preliminari
data
small
number
patient
hmpv
infect
support
hypothesi
reduct
antibiot
prescript
might
achiev
implement
pocmpcr
data
publish
addit
mpcr
grant
new
knowledg
put
common
viral
infect
provid
epidemiolog
data
possibl
correl
patient
clinic
present
detect
pathogen
consequ
find
recommend
perform
pocmpcr
everi
patient
lrt
infect
sinc
unselect
test
associ
signific
expens
without
necessarili
influenc
clinic
decisionmak
contrast
suggest
implement
algorithm
help
increas
pretest
probabl
identifi
children
posit
mpcr
result
prevent
antibiot
therapi
accord
data
children
present
winter
season
rsvlike
symptom
like
cough
airway
obstruct
crackl
auscult
age
year
older
neg
rsvradt
qualifi
pcrbase
pointofcar
test
regard
fig
cutoff
month
allow
detect
mani
children
possibl
suffer
hmpv
infect
children
fals
neg
rsvradt
might
lead
reduct
antibiot
therapi
possibl
shorten
length
antibiot
treatment
improv
rate
crossinfect
inpati
treatment
achiev
well
